Clinical Trial Update: Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing intramuscular olanzapine depot to oral olanzapine and a low-dose depot in patients with schizophrenia. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Olanzapine depot (low-dose, intramuscular) (olanzapine)
• Olanzapine pamoate (intramuscular depot) (olanzapine)
• olanzapine (olanzapine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenic Disorders | Phase 3 | Status: COMPLETED